IS7319A - Fjölgervingar klópídógrelvetnissúlfats - Google Patents

Fjölgervingar klópídógrelvetnissúlfats

Info

Publication number
IS7319A
IS7319A IS7319A IS7319A IS7319A IS 7319 A IS7319 A IS 7319A IS 7319 A IS7319 A IS 7319A IS 7319 A IS7319 A IS 7319A IS 7319 A IS7319 A IS 7319A
Authority
IS
Iceland
Prior art keywords
hydrogen sulphate
clopidogrel hydrogen
multiple synthetic
clopidogrel hydrogensulfate
clopidogrel
Prior art date
Application number
IS7319A
Other languages
English (en)
Inventor
Lifshitz-Liron Revital
Kovalevski-Ishai Eti
Wizel Shlomit
Avhar-Maydan Sharon
Lidor-Hadas Ramy
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/074,409 external-priority patent/US6767913B2/en
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of IS7319A publication Critical patent/IS7319A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Liquid Crystal Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
IS7319A 2001-12-18 2004-06-16 Fjölgervingar klópídógrelvetnissúlfats IS7319A (is)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US34244001P 2001-12-18 2001-12-18
US34235101P 2001-12-21 2001-12-21
US34818202P 2002-01-11 2002-01-11
US10/074,409 US6767913B2 (en) 2001-12-18 2002-02-12 Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms
US35915702P 2002-02-21 2002-02-21
PCT/US2002/040679 WO2003051362A2 (en) 2001-12-18 2002-12-18 Polymorphs of clopidogrel hydrogensulfate

Publications (1)

Publication Number Publication Date
IS7319A true IS7319A (is) 2004-06-16

Family

ID=27536010

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7319A IS7319A (is) 2001-12-18 2004-06-16 Fjölgervingar klópídógrelvetnissúlfats

Country Status (18)

Country Link
EP (1) EP1467735B1 (is)
JP (2) JP2005514387A (is)
KR (1) KR100839136B1 (is)
CN (1) CN1620293A (is)
AT (1) ATE417051T1 (is)
AU (1) AU2002366383B2 (is)
CA (1) CA2470479A1 (is)
DE (1) DE60230327D1 (is)
ES (1) ES2316650T3 (is)
HR (1) HRP20040647A2 (is)
HU (1) HUP0402485A3 (is)
IL (1) IL162461A0 (is)
IS (1) IS7319A (is)
MX (1) MXPA04006088A (is)
NO (1) NO20043038L (is)
PL (1) PL370802A1 (is)
PT (1) PT1467735E (is)
WO (1) WO2003051362A2 (is)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ297472B6 (cs) 2002-08-27 2006-12-13 Zentiva, A.S. Zpusob výroby clopidogrelu hydrogensulfátu krystalické formy I
GB2393181A (en) * 2002-09-19 2004-03-24 Cipla Ltd Amorphous clopidogrel
ITMI20022228A1 (it) * 2002-10-21 2004-04-22 Dinamite Dipharma S P A Sali di clopidogrel con acidi alchil-solforici.
WO2004048385A2 (en) * 2002-11-28 2004-06-10 Instytut Farmaceutyczny A process for the preparation of crystalline form 1 or clopidogrel hydrogen sulfate
WO2004081015A1 (en) * 2003-03-10 2004-09-23 Hetero Drugs Limited Amorphous clopidogrel hydrogen sulfate
WO2004081016A1 (en) 2003-03-12 2004-09-23 Cadila Healthcare Limited Polymorphs and amorphous form of (s) - (+) -clopidogrel bisulfate
CN1812993B (zh) * 2003-07-02 2011-06-29 埃吉斯药物工厂 制备抑制血小板聚集药物的结晶性多晶型物的方法
JP2007516166A (ja) * 2003-07-02 2007-06-21 エギシュ　ヂョヂセルヂャール　エルテー 血小板凝集阻害剤の無晶形の製法
HU0302029D0 (en) * 2003-07-02 2003-09-29 Egyt Gyogyszervegyeszeti Gyar Amorphous form of an anticoagulant agent
DE10337773A1 (de) * 2003-08-13 2005-03-24 Krka Tovarna Zdravil, D.D. Kristallisation von festen Formen von Clopidogrel-Additionssalzen
PT1680430E (pt) 2003-11-03 2010-04-26 Cadila Healthcare Ltd Processos para a preparação da forma i de bissulfato de (s)-(+)-clopidogrel
CA2562532C (en) * 2004-04-09 2010-02-16 Hanmi Pharm. Co., Ltd. Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same
HRP20160757T1 (hr) * 2004-04-19 2016-08-12 Krka, Tovarna Zdravil, D.D., Novo Mesto Postupak za proizvodnju polimorfnog oblika i od klopidogrel-vodik-sulfata
MXPA06012205A (es) * 2004-04-20 2007-01-31 Sanofi Aventis Formas polimorficas de hidrobromuro acetato de metil(+)-(s) - alfa- (2-clorofenil)-6,7-dihidrotieno[3,2-c]piridina-5 (4h), hidrobromuro de clopidogrel.
AU2005236046A1 (en) * 2004-04-20 2005-11-03 Sanofi-Aventis Clopidogrel salt and polymorphic forms thereof
WO2005117866A1 (en) * 2004-06-01 2005-12-15 Ivax Pharmaceuticals S.R.O. Amorphous clopidogrel hydrochloride and its antithrombotic use
EP1693375A1 (en) * 2005-02-21 2006-08-23 KRKA, tovarna zdravil, d.d., Novo mesto Process for preparing clopidrogel hydrogen sulfate of form I
KR20070009851A (ko) * 2005-07-14 2007-01-19 씨제이 주식회사 클로피도그렐 황산수소염 함유 약학 조성물
US20090093635A1 (en) * 2006-03-09 2009-04-09 Sandor Garadnay PROCESS FOR MAKING POLYMORPH FROM I OF (S) - (+) -METHYL-ALPHA- (2-CHLOROPHENYL) -6, 7-DYHIDRO-THIENO- [3, 2-c] PYRIDINE-5 (4H) -ACETATE HYDROGEN SULFATE
SI22383A (sl) * 2006-09-22 2008-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Nov postopek sinteze klopidogrela in nove oblike njegovih farmacevtsko sprejemljivih soli
HUP0600839A3 (en) * 2006-11-14 2008-09-29 Egis Gyogyszergyar Nyrt Solid pharmaceutical composition containing polymorph i of clopidogrel hydrogensulfate and process for the preparation thereof
KR101464482B1 (ko) * 2007-05-08 2014-11-26 경동제약 주식회사 클로피도그렐 황산수소염을 함유하는 약학적 조성물 및 그제조방법
EP2107061A1 (en) 2008-04-02 2009-10-07 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically enriched clopidogrel
KR101130445B1 (ko) * 2009-10-29 2012-03-27 동아제약주식회사 클로피도그랠 황산수소염 ⅰ형 제조방법
CN101962387B (zh) * 2010-09-13 2013-01-30 成都雅途生物技术有限公司 一种新结晶形态的氯吡格雷硫酸氢盐及其制备方法
CN102358743A (zh) * 2011-11-05 2012-02-22 江南大学 一种制备无定形氯吡格雷硫酸氢盐的简便方法
CN103006599A (zh) * 2012-12-31 2013-04-03 广州白云山天心制药股份有限公司 含氯化钠药物载体的抗凝血片剂及其制备方法
CN103408567B (zh) * 2013-07-18 2016-12-28 浙江普洛医药科技有限公司 一种制备硫酸氢氯吡格雷晶型ⅰ的方法
CN104610274B (zh) * 2013-11-05 2017-04-19 亚宝药业集团股份有限公司 一种i型氯吡格雷硫酸氢盐的制备方法
KR102495018B1 (ko) 2013-11-15 2023-02-06 아케비아 테라퓨틱스 인코포레이티드 ｛[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노｝아세트산의 고체형, 이의 조성물 및 용도
CN104045653A (zh) * 2014-07-15 2014-09-17 苏州天马精细化学品股份有限公司 一种硫酸氢氯吡格雷的纯化方法
KR101710922B1 (ko) 2015-06-03 2017-02-28 경동제약 주식회사 클로피도그렐 황산염 결정형 i형의 제조방법
CN107163060B (zh) * 2017-05-24 2021-03-02 常州制药厂有限公司 一种硫酸氢氯吡格雷晶型ii制备方法
CN107337683B (zh) * 2017-08-16 2019-08-16 中荣凯特（北京）生物科技有限公司 一种噻吩并吡啶类衍生物硫酸氢盐的晶型ⅱ及其制备方法和应用
WO2020013305A1 (ja) * 2018-07-12 2020-01-16 有機合成薬品工業株式会社 クロピドグレル硫酸塩のｉ型結晶の製造方法
KR102220480B1 (ko) * 2019-02-13 2021-02-25 한국바이오켐제약 주식회사 클로피도그렐황산염의 제조방법 및 이를 포함하는 약학제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) * 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
FR2664276B1 (fr) * 1990-07-04 1992-10-23 Sanofi Sa Derive thienyl-2 glycidique, son procede de preparation et son utilisation comme intermediaire de synthese.
US5576328A (en) * 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
FR2751540B1 (fr) * 1996-07-26 1998-10-16 Sanofi Sa Composition pharmaceutique antithrombotique
FR2769313B1 (fr) * 1997-10-06 2000-04-21 Sanofi Sa Derives d'esters hydroxyacetiques, leur procede de preparation et leur utilisation comme intermediaires de synthese
FR2779726B1 (fr) * 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
AU2002356430A1 (en) * 2002-12-09 2004-06-30 Hetero Drugs Limited A novel polymorph of clopidogrel hydrogen sulfate

Also Published As

Publication number Publication date
IL162461A0 (en) 2005-11-20
WO2003051362A2 (en) 2003-06-26
EP1467735A2 (en) 2004-10-20
HUP0402485A3 (en) 2008-10-28
CA2470479A1 (en) 2003-06-26
HRP20040647A2 (en) 2005-04-30
JP2005514387A (ja) 2005-05-19
NO20043038L (no) 2004-09-09
KR100839136B1 (ko) 2008-06-20
AU2002366383B2 (en) 2007-06-14
ATE417051T1 (de) 2008-12-15
JP2009108107A (ja) 2009-05-21
HUP0402485A2 (hu) 2005-04-28
KR20040066917A (ko) 2004-07-27
CN1620293A (zh) 2005-05-25
WO2003051362A3 (en) 2003-08-07
EP1467735B1 (en) 2008-12-10
MXPA04006088A (es) 2004-09-27
PL370802A1 (en) 2005-05-30
PT1467735E (pt) 2009-03-10
EP1467735A4 (en) 2005-11-23
DE60230327D1 (de) 2009-01-22
AU2002366383A1 (en) 2003-06-30
ES2316650T3 (es) 2009-04-16

Similar Documents

Publication Publication Date Title
IS7319A (is) Fjölgervingar klópídógrelvetnissúlfats
ATE415966T1 (de) Substituierte 3-amino-thieno(2,3-b)pyridine-2- amide und herstellungsverfahren sowie deren verwendung
BR0014352A (pt) Cetoenóis espirocìclicos substituìdos por trifluormetila
WO2003084922A8 (de) Acyl-4-carboxy-phenyl-harnstoffderivate, verfahren zu deren herstellung und deren verwendung
MXPA05013752A (es) Procedimiento e intermediarios para la preparacion de (1r,2s,5s)-6,6-dimetil-3-azabiciclo[3,1,0]exan-2-carboxilatos o sales de los mismos.
TNSN05007A1 (en) Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof.
DE60231682D1 (de) Naturkautschuk-Masterbatch dessen Herstellungsverfahren, und Naturkautschukzusammensetzung
AU2003285172A8 (en) Human embryonic stem cell cultures, and compositions and methods for growing same
DE60141706D1 (de) Verbindungen mit fungizider wirkung und verfahren zur ihrer herstellung und verwendung
EP1428831A4 (en) METHOD FOR STORING HYDROGEN, HYDROGEN INCLUSION COMPOUND AND METHOD FOR THE PRODUCTION THEREOF
BRPI0414598A (pt) indóis substituìdos
ATE393764T1 (de) Polymorphe formen von valsartan
UA93531C2 (en) Novel hydrogen sulfate salt
WO2006066950A3 (de) Tricyclische aminoalkohole, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
PL370911A1 (pl) Sposoby wytwarzania podstawionych bicyklicznych pochodnych do leczenia nieprawidłowego wzrostu komórek
GB0324210D0 (en) Organic compounds
DK1204659T3 (da) Serotonerge benzofuraner
TW200738608A (en) Organic compounds
IL145339A0 (en) New technology for improving the utilization of sunlight by plants
HRP20051005A2 (en) Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
GB0103240D0 (en) Organic compounds
GB2422842B (en) Process for the production of multipurpose energy sources and multipurpose energy sources produced by said process
DE60323748D1 (de) 1,3-diaza-dibenzoazulene als inhibitoren der produfür deren herstellung
TW200609226A (en) New isobenzoxazinones and their use as ultraviolet light absorbers
TW200503675A (en) Combination of phenylcarboxamides with blockers of the Ikr channel and their use for the treatment of atrial arrhythmias